At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed May 4, 2026 at 16:00 ET
Cytokinetics announced it will report topline results from its ACACIA-HCM trial (aficamten in non-obstructive HCM) on May 5, 2026, with a conference call to follow. No results were disclosed in this press release.
- Topline results from Phase 3 ACACIA-HCM trial to be reported May 5, 2026
- Trial evaluates aficamten in patients with non-obstructive hypertrophic cardiomyopathy
- Conference call scheduled for 8:00 AM ET on May 5
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access